Credit Suisse Group reaffirmed their outperform rating on shares of AstraZeneca (LON:AZN) in a report issued on Wednesday morning, ThisIsMoney.Co.Uk reports.
Other equities analysts have also issued reports about the company. Barclays raised their price target on AstraZeneca from GBX 9,200 ($113.22) to GBX 9,300 ($114.45) and gave the stock an overweight rating in a report on Wednesday. DZ Bank raised their price target on AstraZeneca from GBX 6,500 ($79.99) to GBX 7,300 ($89.84) and gave the stock a sell rating in a report on Friday, May 1st. Oddo Securities lowered AstraZeneca to a reduce rating and cut their price target for the stock from GBX 8,100 ($99.68) to GBX 7,600 ($93.53) in a report on Monday, June 22nd. Jefferies Financial Group reaffirmed a hold rating on shares of AstraZeneca in a report on Thursday, July 9th. Finally, Morgan Stanley reissued an equal weight rating and set a GBX 9,000 ($110.76) price objective on shares of AstraZeneca in a research note on Tuesday, July 21st. Six investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of GBX 8,347.78 ($102.73).
AstraZeneca stock opened at GBX 8,530 ($104.97) on Wednesday. AstraZeneca has a one year low of GBX 83.80 ($1.03) and a one year high of GBX 9,537.09 ($117.37). The business has a fifty day moving average price of GBX 8,583.32 and a 200-day moving average price of GBX 7,938.56. The company has a debt-to-equity ratio of 171.72, a current ratio of 0.75 and a quick ratio of 0.56. The firm has a market capitalization of $111.94 billion and a P/E ratio of 73.73.
The company also recently declared a dividend, which will be paid on Monday, September 14th. Shareholders of record on Thursday, August 13th will be given a dividend of GBX 69.60 ($0.86) per share. The ex-dividend date is Thursday, August 13th. This represents a yield of 0.8%. AstraZeneca’s payout ratio is 188.42%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.